Incidence of Major and Minor Infections/FUO or Herpes Zoster During Remission After Fludarabine Therapy
| . | Time From Discontinuation of Treatment (mo) . | |||||
|---|---|---|---|---|---|---|
| 0-6 . | 7-12 . | 13-18 . | 19-24 . | 25-30 . | 30-36 . | |
| Patients at risk | 137 | 133 | 125 | 113 | 102 | 95 |
| Major* | 4 (2.9%) | 1 (0.8%) | 4 (3.22%) | 3 (2.7%) | 0 (—) | 0 (—) |
| Minor/FUO | 24 (17.5%) | 18 (13.5%) | 12 (9.6%) | 3 (2.7%) | 3 (2.9%) | 4 (4.2%) |
| Herpes zoster | 6 (4.4%) | 6 (4.5%) | 3 (2.4%) | 2 (1.8%) | 1 (1%) | 0 (—) |
| Total | 34 (24.8%) | 25 (18.8%) | 19 (15.5%) | 8 (7.1%) | 4 (3.9%) | 4 (4.2%) |
| . | Time From Discontinuation of Treatment (mo) . | |||||
|---|---|---|---|---|---|---|
| 0-6 . | 7-12 . | 13-18 . | 19-24 . | 25-30 . | 30-36 . | |
| Patients at risk | 137 | 133 | 125 | 113 | 102 | 95 |
| Major* | 4 (2.9%) | 1 (0.8%) | 4 (3.22%) | 3 (2.7%) | 0 (—) | 0 (—) |
| Minor/FUO | 24 (17.5%) | 18 (13.5%) | 12 (9.6%) | 3 (2.7%) | 3 (2.9%) | 4 (4.2%) |
| Herpes zoster | 6 (4.4%) | 6 (4.5%) | 3 (2.4%) | 2 (1.8%) | 1 (1%) | 0 (—) |
| Total | 34 (24.8%) | 25 (18.8%) | 19 (15.5%) | 8 (7.1%) | 4 (3.9%) | 4 (4.2%) |
*Pneumonia and/or septicemia.